Engineering Medicines To Improve Patient Care
Elevating
Therapeutics
We are committed to developing best-in-class
therapeutic antibodies to improve patient care.
Our Lead Programs
Our therapeutic programs harness groundbreaking clinical discoveries and proven technologies to craft best-in-class monoclonal antibodies.
VRDN-001
An anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody in development for thyroid eye disease (TED)
Learn MoreVRDN-002
A distinct IGF-1R monoclonal antibody that incorporates half-life extension technology and is designed for subcutaneous injection for the treatment of TED
Learn MoreVRDN-003
A monoclonal antibody that incorporates half-life extension technology into the sequence of VRDN-001 and is designed for subcutaneous injection for the treatment of TED
Learn More
Treatments
Targeting
Patient Needs
We are dedicated to creating solutions for patients’ most pressing needs. Learn more about our initial programs for patients suffering from Thyroid Eye Disease.
Viridian Announces
Positive Low Dose
VRDN-001 Clinical Data
Significant and rapid improvement in both signs and symptoms of TED after
two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg results
A New Path to Better Medicines
We have reimagined therapeutics research and development, accelerating the transformational benefits biotechnology can offer to patients suffering from serious diseases.
Learn MoreNovel Therapeutics Designed For Impact
Our pipeline of candidate therapeutics reflects a patient-centric model of innovation. We leverage proven biology and technology to efficiently craft medicines to meet the needs of patients and healthcare providers.